Table 1 Patients’ characteristics
Characteristics | PIPC/TAZ (n = 163) | CFPM (n = 103) | p-value |
|---|---|---|---|
Age (years) | |||
Median (range) | 76.0 (21 – 96) | 75.0 (26 – 95) | 0.99 |
Female, n (%) | 61 (37.4) | 24 (23.3) | 0.021 |
Dose frequency per day, n | |||
1, 2, 3, 4 | 0, 15, 139, 9 | 6, 90, 7, 0 | - |
Duration of therapy (days) | |||
Median (range) | 6 (2 – 24) | 8 (3 – 26) | < 0.001 |
Infectious diagnosis, n (%) | |||
Respiratory tract | 75 (46) | 58 (56) | - |
Abdomen | 36 (22) | 6 (6) | - |
Urinary tract | 15 (9) | 7 (7) | - |
Neutropenia | 10 (6) | 18 (18) | - |
Sepsis | 8 (5) | 4 (4) | - |
Fever of unknown origin | 8 (5) | 7 (7) | - |
Skin and soft tissue | 5 (3) | 1 (1) | - |
Catheter-associated BSI | 3 (2) | 2 (2) | - |
Head and neck | 3 (2) | 0 | - |
Eye | 0 | 1 (1) | - |
Comorbidity, n (%) | |||
Hypertension | 84 (52) | 46 (45) | 0.31 |
Heart failure | 26 (16) | 13 (13) | 0.48 |
Diabetes | 46 (28) | 26 (25) | 0.67 |
Malignancy | 49 (30) | 44 (42) | 0.047 |
Prostatic hypertrophy | 32 (20) | 17 (17) | 0.63 |
Chronic kidney disease | 68 (42) | 39 (38) | 0.61 |
30-day mortality, n (%) | 10 (6.1) | 9 (8.7) | 0.42 |
Serum creatinine (mg/dL) | |||
Median (IQR) | 0.92 (0.66 – 1.25) | 0.84 (0.64 – 1.29) | 0.68 |
eGFR (mL/min/1.73m2 ) | |||
Median (IQR) | 62.5 (40.2 – 80.8) | 64.9 (40.1 – 86.3) | 0.35 |
Concomitant, n (%) | |||
Contrast media | 28 (17) | 2 (2) | < 0.001 |
NSAIDs (i.v. or p.o.) | 66 (41) | 63 (63) | 0.0011 |
ACE-I / ARB | 50 (31) | 29 (27) | 0.68 |
Diuretics | 37 (23) | 29 (28) | 0.38 |
Calcineurin inhibitors (p.o.) | 1 (0.6) | 1 (0.9) | 1 |
Catecholamine | 8 (5) | 2 (2) | 0.32 |
Aminoglycoside (i.v.) | 1 (0.6) | 1 (0.9) | 1 |
Acyclovir (p.o.) | 1 (0.6) | 0 | 1 |
Cisplatin | 1 (0.6) | 0 | 1 |